Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

698 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development and validation of time-to-event models to predict metastatic recurrence of localized cutaneous melanoma.
Wan G, Leung BW, DeSimone MS, Nguyen N, Rajeh A, Collier MR, Rashdan H, Roster K, Zhou X, Moseley CB, Nirmal AJ, Pelletier RJ, Maliga Z, Marko-Varga G, Németh IB, Tsao H, Asgari MM, Gusev A, Stagner AM, Lian CG, Hurlbert MS, Liu F, Yu KH, Sorger PK, Semenov YR. Wan G, et al. Among authors: yu kh. J Am Acad Dermatol. 2024 Feb;90(2):288-298. doi: 10.1016/j.jaad.2023.08.105. Epub 2023 Oct 4. J Am Acad Dermatol. 2024. PMID: 37797836
Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
Kalinich M, Murphy W, Wongvibulsin S, Pahalyants V, Yu KH, Lu C, Wang F, Zubiri L, Naranbhai V, Gusev A, Kwatra SG, Reynolds KL, Semenov YR. Kalinich M, et al. Among authors: yu kh. J Immunother Cancer. 2021 Mar;9(3):e001935. doi: 10.1136/jitc-2020-001935. J Immunother Cancer. 2021. PMID: 33789879 Free PMC article.
Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis.
Wongvibulsin S, Pahalyants V, Kalinich M, Murphy W, Yu KH, Wang F, Chen ST, Reynolds K, Kwatra SG, Semenov YR. Wongvibulsin S, et al. Among authors: yu kh. J Am Acad Dermatol. 2022 Mar;86(3):563-572. doi: 10.1016/j.jaad.2021.03.094. Epub 2021 Apr 2. J Am Acad Dermatol. 2022. PMID: 33819538 Free PMC article.
Prediction of early-stage melanoma recurrence using clinical and histopathologic features.
Wan G, Nguyen N, Liu F, DeSimone MS, Leung BW, Rajeh A, Collier MR, Choi MS, Amadife M, Tang K, Zhang S, Phillipps JS, Jairath R, Alexander NA, Hua Y, Jiao M, Chen W, Ho D, Duey S, Németh IB, Marko-Varga G, Valdés JG, Liu D, Boland GM, Gusev A, Sorger PK, Yu KH, Semenov YR. Wan G, et al. Among authors: yu kh. NPJ Precis Oncol. 2022 Oct 31;6(1):79. doi: 10.1038/s41698-022-00321-4. NPJ Precis Oncol. 2022. PMID: 36316482 Free PMC article.
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study.
Zhang S, Tang K, Wan G, Nguyen N, Lu C, Ugwu-Dike P, Raval N, Seo J, Alexander NA, Jairath R, Phillipps J, Leung BW, Roster K, Chen W, Zubiri L, Boland G, Chen ST, Tsao H, Demehri S, LeBoeuf NR, Reynolds KL, Yu KH, Gusev A, Kwatra SG, Semenov YR. Zhang S, et al. Among authors: yu kh. medRxiv [Preprint]. 2023 Jan 18:2023.01.16.23284635. doi: 10.1101/2023.01.16.23284635. medRxiv. 2023. Update in: J Am Acad Dermatol. 2023 May;88(5):1024-1032. doi: 10.1016/j.jaad.2022.12.048 PMID: 36711758 Free PMC article. Updated. Preprint.
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study.
Zhang S, Tang K, Wan G, Nguyen N, Lu C, Ugwu-Dike P, Raval N, Seo J, Alexander NA, Jairath R, Phillipps J, Leung BW, Roster K, Chen W, Zubiri L, Boland G, Chen ST, Tsao H, Demehri S, LeBoeuf NR, Reynolds KL, Yu KH, Gusev A, Kwatra SG, Semenov YR. Zhang S, et al. Among authors: yu kh. J Am Acad Dermatol. 2023 May;88(5):1024-1032. doi: 10.1016/j.jaad.2022.12.048. Epub 2023 Feb 2. J Am Acad Dermatol. 2023. PMID: 36736626 Free PMC article.
Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy.
Nguyen N, Wan G, Ugwu-Dike P, Alexander NA, Raval N, Zhang S, Jairath R, Phillipps J, Leung B, Roster K, Seo J, Lu C, Tang K, Choi MS, DeSimone MS, Theodosakis N, Amadife M, Cox N, Le TK, Liu F, Chen W, Bai X, Boland G, Liu D, Hurlbert MS, LeBoeuf N, Reynolds KL, Yu KH, Tsao H, Asgari M, Gusev A, Kwatra SG, Semenov YR. Nguyen N, et al. Among authors: yu kh. J Am Acad Dermatol. 2023 Jun;88(6):1308-1316. doi: 10.1016/j.jaad.2023.02.014. Epub 2023 Feb 22. J Am Acad Dermatol. 2023. PMID: 36828138 Free PMC article.
Mitochondrial and immune response dysregulation in melanoma recurrence.
Szadai L, Guedes JS, Woldmar N, de Almeida NP, Jánosi ÁJ, Rajeh A, Kovács F, Kriston A, Migh E, Wan G, Nguyen N, Oskolás H, Appelqvist R, Nogueira FC, Domont GB, Yu KH, Semenov ER, Malm J, Rezeli M, Wieslander E, Fenyö D, Kemény L, Horvath P, Németh IB, Marko-Varga G, Gil J. Szadai L, et al. Among authors: yu kh. Clin Transl Med. 2023 Nov;13(11):e1495. doi: 10.1002/ctm2.1495. Clin Transl Med. 2023. PMID: 37990633 Free PMC article. No abstract available.
698 results